<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p253" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_253{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_253{left:306px;bottom:30px;}
#t3_253{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_253{left:346px;bottom:30px;}
#t5_253{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_253{left:517px;bottom:30px;}
#t7_253{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_253{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_253{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_253{left:1105px;bottom:27px;letter-spacing:0.25px;}
#tb_253{left:35px;bottom:777px;letter-spacing:0.08px;word-spacing:0.1px;}
#tc_253{left:35px;bottom:757px;letter-spacing:0.16px;}
#td_253{left:405px;bottom:757px;}
#te_253{left:35px;bottom:722px;letter-spacing:0.05px;word-spacing:-0.65px;}
#tf_253{left:35px;bottom:702px;letter-spacing:0.12px;word-spacing:0.07px;}
#tg_253{left:35px;bottom:683px;letter-spacing:0.06px;word-spacing:0.13px;}
#th_253{left:35px;bottom:665px;letter-spacing:0.11px;word-spacing:0.08px;}
#ti_253{left:35px;bottom:645px;letter-spacing:0.19px;}
#tj_253{left:548px;bottom:645px;}
#tk_253{left:35px;bottom:608px;letter-spacing:0.04px;word-spacing:0.15px;}
#tl_253{left:35px;bottom:589px;letter-spacing:0.07px;word-spacing:0.12px;}
#tm_253{left:35px;bottom:570px;letter-spacing:0.08px;word-spacing:0.11px;}
#tn_253{left:35px;bottom:551px;letter-spacing:0.16px;}
#to_253{left:405px;bottom:551px;}
#tp_253{left:35px;bottom:514px;letter-spacing:0.12px;word-spacing:-0.35px;}
#tq_253{left:35px;bottom:495px;letter-spacing:-0.06px;word-spacing:0.25px;}
#tr_253{left:35px;bottom:476px;letter-spacing:0.11px;word-spacing:0.08px;}
#ts_253{left:35px;bottom:457px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tt_253{left:132px;bottom:457px;letter-spacing:0.16px;}
#tu_253{left:501px;bottom:457px;}
#tv_253{left:35px;bottom:420px;letter-spacing:0.09px;word-spacing:0.09px;}
#tw_253{left:35px;bottom:401px;letter-spacing:0.16px;word-spacing:0.03px;}
#tx_253{left:35px;bottom:382px;letter-spacing:0.18px;word-spacing:0.01px;}
#ty_253{left:35px;bottom:363px;letter-spacing:0.06px;word-spacing:0.13px;}
#tz_253{left:35px;bottom:343px;letter-spacing:0.16px;}
#t10_253{left:405px;bottom:343px;}
#t11_253{left:35px;bottom:306px;letter-spacing:0.02px;word-spacing:0.16px;}
#t12_253{left:35px;bottom:288px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t13_253{left:35px;bottom:269px;letter-spacing:0.12px;word-spacing:0.06px;}
#t14_253{left:35px;bottom:249px;letter-spacing:0.16px;}
#t15_253{left:386px;bottom:249px;}
#t16_253{left:35px;bottom:212px;letter-spacing:0.05px;word-spacing:0.14px;}
#t17_253{left:35px;bottom:194px;letter-spacing:0.1px;word-spacing:0.09px;}
#t18_253{left:35px;bottom:174px;letter-spacing:0.03px;word-spacing:-0.66px;}
#t19_253{left:35px;bottom:155px;letter-spacing:-0.38px;}
#t1a_253{left:59px;bottom:155px;letter-spacing:0.16px;}
#t1b_253{left:419px;bottom:155px;}
#t1c_253{left:35px;bottom:118px;letter-spacing:-0.04px;word-spacing:0.22px;}
#t1d_253{left:35px;bottom:100px;letter-spacing:-0.06px;word-spacing:0.24px;}
#t1e_253{left:35px;bottom:80px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1f_253{left:618px;bottom:777px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1g_253{left:618px;bottom:757px;letter-spacing:0.16px;}
#t1h_253{left:988px;bottom:757px;}
#t1i_253{left:618px;bottom:722px;letter-spacing:0.05px;word-spacing:-0.28px;}
#t1j_253{left:618px;bottom:702px;word-spacing:0.18px;}
#t1k_253{left:618px;bottom:683px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1l_253{left:618px;bottom:663px;letter-spacing:0.16px;}
#t1m_253{left:988px;bottom:663px;}
#t1n_253{left:618px;bottom:628px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1o_253{left:618px;bottom:608px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1p_253{left:618px;bottom:589px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1q_253{left:618px;bottom:570px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1r_253{left:618px;bottom:551px;letter-spacing:0.16px;}
#t1s_253{left:988px;bottom:551px;}
#t1t_253{left:618px;bottom:514px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1u_253{left:618px;bottom:495px;letter-spacing:0.09px;word-spacing:-0.87px;}
#t1v_253{left:618px;bottom:476px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1w_253{left:618px;bottom:457px;letter-spacing:0.16px;}
#t1x_253{left:979px;bottom:457px;}
#t1y_253{left:618px;bottom:420px;letter-spacing:-0.03px;word-spacing:-0.22px;}
#t1z_253{left:618px;bottom:401px;letter-spacing:0.08px;word-spacing:0.11px;}
#t20_253{left:618px;bottom:382px;letter-spacing:0.08px;word-spacing:0.11px;}
#t21_253{left:618px;bottom:363px;letter-spacing:0.16px;}
#t22_253{left:988px;bottom:363px;}
#t23_253{left:618px;bottom:326px;letter-spacing:0.08px;word-spacing:0.11px;}
#t24_253{left:618px;bottom:306px;word-spacing:0.19px;}
#t25_253{left:618px;bottom:288px;letter-spacing:0.08px;word-spacing:0.1px;}
#t26_253{left:618px;bottom:269px;letter-spacing:0.16px;}
#t27_253{left:988px;bottom:269px;}
#t28_253{left:618px;bottom:232px;letter-spacing:0.07px;word-spacing:-0.42px;}
#t29_253{left:618px;bottom:212px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2a_253{left:618px;bottom:194px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2b_253{left:618px;bottom:174px;letter-spacing:0.16px;}
#t2c_253{left:988px;bottom:174px;}
#t2d_253{left:618px;bottom:138px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2e_253{left:618px;bottom:118px;letter-spacing:0.04px;word-spacing:-0.95px;}
#t2f_253{left:618px;bottom:100px;letter-spacing:0.04px;word-spacing:-1.08px;}
#t2g_253{left:618px;bottom:80px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2h_253{left:618px;bottom:61px;letter-spacing:0.16px;}
#t2i_253{left:988px;bottom:61px;}
#t2j_253{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_253{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_253{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_253{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_253{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_253{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_253{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_253{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts253" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg253Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg253" style="-webkit-user-select: none;"><object width="1210" height="935" data="253/253.svg" type="image/svg+xml" id="pdf253" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_253" class="t s0_253">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_253" class="t s1_253">© </span>
<span id="t3_253" class="t s0_253">(NCCN </span>
<span id="t4_253" class="t s1_253">© </span>
<span id="t5_253" class="t s0_253">), All rights reserved. NCCN Guidelines </span>
<span id="t6_253" class="t s1_253">® </span>
<span id="t7_253" class="t s0_253">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_253" class="t s2_253">NCCN Guidelines Version 4.2024 </span>
<span id="t9_253" class="t s2_253">Head and Neck Cancers </span>
<span id="ta_253" class="t s3_253">MS-112 </span>
<span id="tb_253" class="t s4_253">2020;31:412-421. Available at: </span>
<span id="tc_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/32067683</span><span id="td_253" class="t s4_253">. </span>
<span id="te_253" class="t s4_253">723. Bando H, Kinoshita I, Modi S, et al. Trastuzumab deruxtecan (T-DXd) </span>
<span id="tf_253" class="t s4_253">in patients with human epidermal growth factor receptor 2 (HER2)- </span>
<span id="tg_253" class="t s4_253">expressing salivary duct carcinoma: subgroup analysis of two phase 1 </span>
<span id="th_253" class="t s4_253">studies. Journal of Clinical Oncology 2021;39:6079-6079. Available at: </span>
<span id="ti_253" class="t s5_253">https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.6079</span><span id="tj_253" class="t s4_253">. </span>
<span id="tk_253" class="t s4_253">724. Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab </span>
<span id="tl_253" class="t s4_253">deruxtecan: a dose-expansion, phase I study in multiple advanced solid </span>
<span id="tm_253" class="t s4_253">tumors. Cancer Discov 2020;10:688-701. Available at: </span>
<span id="tn_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/32213540</span><span id="to_253" class="t s4_253">. </span>
<span id="tp_253" class="t s4_253">725. Lin VTG, Nabell LM, Spencer SA, et al. First-line treatment of widely </span>
<span id="tq_253" class="t s4_253">metastatic BRAF-mutated salivary duct carcinoma with combined BRAF </span>
<span id="tr_253" class="t s4_253">and MEK inhibition. J Natl Compr Canc Netw 2018;16:1166-1170. </span>
<span id="ts_253" class="t s4_253">Available at: </span><span id="tt_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/30323086</span><span id="tu_253" class="t s4_253">. </span>
<span id="tv_253" class="t s4_253">726. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and </span>
<span id="tw_253" class="t s4_253">safety of selpercatinib in patients with RET fusion-positive solid tumours </span>
<span id="tx_253" class="t s4_253">other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open- </span>
<span id="ty_253" class="t s4_253">label, basket trial. Lancet Oncol 2022;23:1261-1273. Available at: </span>
<span id="tz_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/36108661</span><span id="t10_253" class="t s4_253">. </span>
<span id="t11_253" class="t s4_253">727. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and </span>
<span id="t12_253" class="t s4_253">cyclophosphamide in advanced salivary gland carcinoma. A phase II trial </span>
<span id="t13_253" class="t s4_253">of 22 patients. Ann Oncol 1996;7:640-642. Available at: </span>
<span id="t14_253" class="t s5_253">http://www.ncbi.nlm.nih.gov/pubmed/8879381</span><span id="t15_253" class="t s4_253">. </span>
<span id="t16_253" class="t s4_253">728. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial </span>
<span id="t17_253" class="t s4_253">comparing vinorelbine versus vinorelbine plus cisplatin in patients with </span>
<span id="t18_253" class="t s4_253">recurrent salivary gland malignancies. Cancer 2001;91:541-547. Available </span>
<span id="t19_253" class="t s4_253">at: </span><span id="t1a_253" class="t s5_253">http://www.ncbi.nlm.nih.gov/pubmed/11169936</span><span id="t1b_253" class="t s4_253">. </span>
<span id="t1c_253" class="t s4_253">729. Nakano K, Sato Y, Sasaki T, et al. Combination chemotherapy of </span>
<span id="t1d_253" class="t s4_253">carboplatin and paclitaxel for advanced/metastatic salivary gland </span>
<span id="t1e_253" class="t s4_253">carcinoma patients: differences in responses by different pathological </span>
<span id="t1f_253" class="t s4_253">diagnoses. Acta Otolaryngol 2016;136:948-951. Available at: </span>
<span id="t1g_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/27094013</span><span id="t1h_253" class="t s4_253">. </span>
<span id="t1i_253" class="t s4_253">730. Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and </span>
<span id="t1j_253" class="t s4_253">gemcitabine in patients with advanced salivary gland cancer: a trial of the </span>
<span id="t1k_253" class="t s4_253">NCIC Clinical Trials Group. Cancer 2010;116:362-368. Available at: </span>
<span id="t1l_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/19924794</span><span id="t1m_253" class="t s4_253">. </span>
<span id="t1n_253" class="t s4_253">731. Sousa LG, Wang K, Torman D, et al. Treatment patterns and </span>
<span id="t1o_253" class="t s4_253">outcomes of palliative systemic therapy in patients with salivary duct </span>
<span id="t1p_253" class="t s4_253">carcinoma and adenocarcinoma, not otherwise specified. Cancer </span>
<span id="t1q_253" class="t s4_253">2022;128:509-518. Available at: </span>
<span id="t1r_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/34661906</span><span id="t1s_253" class="t s4_253">. </span>
<span id="t1t_253" class="t s4_253">732. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland </span>
<span id="t1u_253" class="t s4_253">malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. </span>
<span id="t1v_253" class="t s4_253">Head Neck 2006;28:197-204. Available at: </span>
<span id="t1w_253" class="t s5_253">http://www.ncbi.nlm.nih.gov/pubmed/16470745</span><span id="t1x_253" class="t s4_253">. </span>
<span id="t1y_253" class="t s4_253">733. Locati LD, Cavalieri S, Bergamini C, et al. Phase II trial with axitinib in </span>
<span id="t1z_253" class="t s4_253">recurrent and/or metastatic salivary gland cancers of the upper </span>
<span id="t20_253" class="t s4_253">aerodigestive tract. Head Neck 2019;41:3670-3676. Available at: </span>
<span id="t21_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/31355973</span><span id="t22_253" class="t s4_253">. </span>
<span id="t23_253" class="t s4_253">734. Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in </span>
<span id="t24_253" class="t s4_253">advanced salivary adenoid cystic carcinoma of the head and neck. Head </span>
<span id="t25_253" class="t s4_253">Neck 2015;37:182-187. Available at: </span>
<span id="t26_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/24346857</span><span id="t27_253" class="t s4_253">. </span>
<span id="t28_253" class="t s4_253">735. Ferrarotto R, Sousa LG, Feng L, et al. Phase II clinical trial of axitinib </span>
<span id="t29_253" class="t s4_253">and avelumab in patients with recurrent/metastatic adenoid cystic </span>
<span id="t2a_253" class="t s4_253">carcinoma. J Clin Oncol 2023;41:2843-2851. Available at: </span>
<span id="t2b_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/36898078</span><span id="t2c_253" class="t s4_253">. </span>
<span id="t2d_253" class="t s4_253">736. Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in </span>
<span id="t2e_253" class="t s4_253">recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary </span>
<span id="t2f_253" class="t s4_253">glands: current progress and challenges in evaluating molecularly targeted </span>
<span id="t2g_253" class="t s4_253">agents in ACC. Ann Oncol 2012;23:1562-1570. Available at: </span>
<span id="t2h_253" class="t s5_253">https://www.ncbi.nlm.nih.gov/pubmed/22080184</span><span id="t2i_253" class="t s4_253">. </span>
<span id="t2j_253" class="t s6_253">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
